Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer
The purpose of this study is to determine the maximum safe dose of orally administered Karenitecin (BNP1350) in patients with solid tumors.
Carcinoma|Carcinoma, Non-Small-Cell Lung
DRUG: Karenitecin (BNP1350)
Overall Safety and determination of MTD, and recommended Phase 2 dose, throughout study
Pharmacokinetics, various timepoints|Tumor response, various timepoints
Initially, the safety, side effects and recommended phase 2 dose of oral Karenitecin in patients with advanced solid tumors will be determined.

When the recommended phase 2 dose has been determined, the specified dose will be used to determine if Karenitecin is effective in the treatment of patients with relapsed or refractory non-small cell lung cancer.